CompletedNot Applicable

Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients

Belgium112 participantsStarted 2015-08

Plain-language summary

The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Out-of-hospital CA of presumed cardiac cause irrespective of the presenting rhythm
✓. Unconsciousness (Glasgow coma scale \< 8) at hospital admission
✓. Age ≥ 18 years
✓. Sustained return of spontaneous circulation (ROSC) (=when chest compressions have not been required for 20 consecutive minutes)

Exclusion criteria

✕. Suspected or confirmed intracranial bleeding or stroke
✕. Known limitations in therapy or Do Not Resuscitate-order
✕. Known disease compromising 180 day survival
✕. Known pre-CA cerebral performance category 3-4
✕. Previous stroke (TIA can be included)
✕. MRI incompatible cardiac or neurosurgical device
✕. Systolic blood pressure \< 90 mmHg on norepinephrine \> 1 mcg/kg/min).
✕. Open chest

What they're measuring

% of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI)

Timeframe: day 4-5

Trial details

NCT IDNCT02541591

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06

Results submitted2023-10-20

View on ClinicalTrials.gov More Cerebral Ischemia trials